en · de · es · fr · pt
thymosin-alpha-1-notes.peptides4800.com › Wiki › Background And Molecular Identity — Explained

Background And Molecular Identity — Explained

By Editorial Desk · published 2026-05-05 · last reviewed 2026-05-19 · Wiki

A practical reference on prothymosin alpha: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.

This page was last updated on 2026-05-19 and is reviewed periodically as new material appears.

Background and Molecular Identity

Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.

The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.

Molecular Background and Identity

Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.

Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.

Thymosin-alpha-1 at a glance

PropertyValueNotes
Molecular massAbout 3.1 kDa28 residues, N-terminally acetylated
AppearanceWhite to off-white powderLyophilized solid
SolubilityFreely soluble in waterAlso soluble in aqueous buffers
Storage temperature2 to 8 °CProtect from light and moisture
Common synonymsThymalfasin; Tα1Same peptide sequence

Background and Molecular Profile

Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.

The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.

Related pages on this site

Background and Mechanism of Action

Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.

Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.

Background from the literature

The Cochrane reviews on the treatment of ADHD in children, adolescents, and adults with pharmaceutical amphetamines stated that short-term studies have demonstrated that these drugs decrease the severity of symptoms, but they have higher discontinuation rates than non-stimulant medications due to their adverse side effects. However, a 2025 meta-analytic systematic review of 113 randomized controlled trials found that stimulant medications were the only intervention with robust short-term efficacy, and were associated with lower all-cause treatment discontinuation rates than non-stimulant medications (e.g., atomoxetine). A Cochrane review on the treatment of ADHD in children with tic disorders such as Tourette syndrome indicated that stimulants in general do not make tics worse, but high doses of dextroamphetamine could exacerbate tics in some individuals.

=== Total bilirubin === Total bilirubin = direct bilirubin + indirect bilirubin Elevation of both alanine aminotransferase (ALT) and bilirubin is more indicative of serious liver injury than is elevation in ALT alone, as postulated in Hy's law that elucidates the relation between the lab test results and drug-induced liver injury

ATC code N05 Psycholeptics is a therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products. Subgroup N05 is part of the anatomical group N Nervous system. Codes for veterinary use (ATCvet codes) can be created by placing the letter Q in front of the human ATC code: for example, QN05. ATCvet codes without corresponding human ATC codes are cited with the leading Q in the following list.National versions of the ATC classification may include additional codes not present in this list, which follows the WHO version.

Sources: en.wikipedia.org

Reference notes

Since 1997, the US federal government has prohibited the harvesting of white sharks in US waters, requiring that any incidentally caught shark be released immediately. Management of the species is split by region: the 2006 Consolidated Atlantic Highly Migratory Species Fishery Management Plan covers the Atlantic, while the Pacific Fishery Management Council oversees the Pacific. The white shark also receives protection in National Marine Sanctuaries managed by the National Oceanic and Atmospheric Administration. Some states provide additional safeguards. California has protected the species within its waters (up to 3 miles (4.8 km) offshore) since 1994 and in 2013, added white sharks to the California Endangered Species Act, which introduced strict permit requirements for both scientific research and incidental bycatch. In 2019, the state further banned the use of bait, chum, or decoys to lure white sharks in state waters and prohibited their use within one nautical mile of any shoreline or pier when a shark is present. A 2014 study estimated the white shark population along the California coastline to be approximately 2,400 individuals. Massachusetts also provides state-level protection, having prohibited the capture of white sharks in 2005 and banning the use of chum or bait to lure them in 2015. In 2025, authorities restricted shore-based fishing around Cape Cod in response to viral videos of anglers catching white sharks.

== Political implications == Allenby and Garreau propose that the Great Chain of Being, as developed within medieval Christian thought, helped legitimize political hierarchy and discourage rebellion for centuries. Both Catholic and later Protestant rulers appealed to this worldview. For example, the Protestant King James I himself wrote, "The state of monarchy is the most supreme thing upon earth: for kings are not only God's Lieutenants upon earth, and sit upon God's throne, but even by God himself they are called Gods."

=== Food fraud === In the United States, from 2008 to 2012, some people reported a bitter metallic taste ("pine mouth") that sometimes lasted for weeks after they ate pine nuts. After an international investigation, the FDA found that some manufacturers substituted a non-food species of pine nuts in place of more expensive edible pine nut species as a form of food fraud.

Sources: en.wikipedia.org

Notes from published material

This method involves coating LEDs of one color (mostly blue LEDs made of InGaN) with phosphors of different colors to form white light; the resultant LEDs are called phosphor-based or phosphor-converted white LEDs (pcLEDs). A fraction of the blue light undergoes the Stokes shift, which transforms it from shorter wavelengths to longer. Depending on the original LED's color, various color phosphors are used. Using several phosphor layers of distinct colors broadens the emitted spectrum, effectively raising the color rendering index (CRI). Phosphor-based LEDs have efficiency losses due to heat loss from the Stokes shift and other phosphor-related issues. Their luminous efficacies compared to normal LEDs depend on the spectral distribution of the resultant light output and the original wavelength of the LED itself. For example, the luminous efficacy of a typical YAG yellow phosphor based white LED ranges from 3 to 5 times the luminous efficacy of the original blue LED because of the human eye's greater sensitivity to yellow than to blue (as modeled in the luminosity function). Due to the simplicity of manufacturing, the phosphor method is still the most popular method for making high-intensity white LEDs. The design and production of a light source or light fixture using a monochrome emitter with phosphor conversion is simpler and cheaper than a complex RGB system, and the majority of high-intensity white LEDs presently on the market are manufactured using phosphor light conversion.

==== Officer of the Order of the British Empire (OBE) ==== Military Commander Trefor Morgan Fox, Royal Navy, C037045S. Commander Christopher Robert Hollingworth, Royal Navy, C041543F. Colonel Andrew Glenn David Lock, Royal Marines, N029023U. Commander Lucy Jane Ottley, Royal Navy, V030919T. Commander Ian Hayden Richardson, Royal Navy, C038366T. Commander Jamie Duncan Wells, Royal Navy, C039514F. Captain Allan Thomas Youp, Royal Navy, C038889U. Lieutenant Colonel Nicholas Paul Andrew, Royal Regiment of Artillery, 537949. Lieutenant Colonel Tracy-Louise Appleyard, Royal Army Medical Corps, 540495. Colonel Edward Hugh James Carter, 532335. Lieutenant Colonel Ewan Christian Noble Harris, The Royal Welsh, 545550. Lieutenant Colonel Timothy Matthew Holmes, Corps of Royal Electrical and Mechanical Engineers, 546527. Colonel Matthew Gordon Timothy Lewis, 554319. Lieutenant Colonel (now Acting Colonel) John Andrew Lyons, Royal Corps of Signals, 549561. Lieutenant Colonel Craig David Pope, Royal Army Medical Corps, 549180. Colonel Nigel Offley Crewe-Read, , 545207. Colonel Thomas Woolley, 551152. Colonel Nicholas George Charles Yardley, 544447. Wing Commander Erica Jane Ferguson, Royal Air Force, 2629012K. Wing Commander Matthew Elfed Lewis, Royal Air Force, 5208143G. Wing Commander Stephen McCleery, Royal Air Force, 2635078L. Wing Commander Alison Morton, Royal Air Force, W996632T. Air Commodore Patrick James Shea-Simonds, Royal Air Force, 5208323H. Group Captain Paul Andrew Weaver Smith, Royal Air Force, 8024057B.

=== In the United States of America === Clinical pathologists work in close collaboration with clinical scientists (clinical biochemists, clinical microbiologists, etc.), medical technologists, hospital administrators, and referring physicians to ensure the accuracy and optimal utilization of laboratory testing. Clinical pathology is one of the two major divisions of pathology, the other being anatomical pathology. Often, pathologists practice both anatomical and clinical pathology, a combination sometimes known as general pathology. Similar specialties exist in veterinary pathology. Clinical pathology is itself divided into subspecialties, the main ones being clinical chemistry, clinical hematology/blood banking, hematopathology and clinical microbiology and emerging subspecialties such as molecular diagnostics and proteomics. Many areas of clinical pathology overlap with anatomic pathology. Both can serve as medical directors of CLIA certified laboratories. Under the CLIA law, only the US Department of Health and Human Services approved Board Certified Ph.D., DSc, or MD and DO can perform the duties of a Medical or Clinical Laboratory Director. This overlap includes immunoassays, flow cytometry, microbiology and cytogenetics and any assay done on tissue. Overlap between anatomic and clinical pathology is expanding to molecular diagnostics and proteomics as we move towards making the best use of new technologies for personalized medicine.

Schotten–Baumann reaction conditions can also refer to the formation of esters by reaction of an acyl chloride with a primary or secondary alcohol. The reaction was first described in 1883 by German chemists Carl Schotten and Eugen Baumann. The name "Schotten–Baumann reaction conditions" often indicate the use of a two-phase solvent system, consisting of water and an organic solvent. The base in the water phase neutralizes the acid generated by the reaction while the starting materials and product remain in the organic phase, often dichloromethane or diethyl ether.

Sources: en.wikipedia.org

Frequently asked questions

What is thymosin alpha-1?

It is a 28-residue synthetic peptide studied as an immune-modulating agent and approved as a drug in some countries. The sequence matches a naturally occurring fragment isolated from thymus tissue. It is not a hormone in the endocrine sense.

Where does the name come from?

The name traces back to thymosin fraction 5, a crude thymus extract examined in the 1970s. Individual peptides in that mixture were labeled with Greek letters, and alpha-1 was one of them. The international nonproprietary name thymalfasin was assigned later.

Is it the same as thymosin beta-4?

No. Thymosin beta-4 contains 43 residues and binds actin, while thymosin alpha-1 contains 28 residues and acts on immune cells. The two sit in a historical naming group but share no sequence similarity, and they are not substitutes for one another.

Is thymosin alpha 1 a hormone?

The name reflects an early convention for naming thymus-derived fractions. The peptide is characterized and measured as a defined molecule, and it does not operate through a single classical endocrine axis.

Network